UCB
Key Presentations at JPM25: AbbVie, UCB, WuXi Biologics Highlight Industry Trends
JPM25, J.P. Morgan Healthcare Conference, AbbVie, UCB, WuXi Biologics, Biotech Trends, Healthcare Innovation
UCB and Novartis Discontinue Development of Parkinson’s Disease Drug After Phase 2 Failure
UCB, Novartis, Parkinson’s disease, drug development, Phase 2 failure, UCB0599, UCB7853
GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others
GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying
Roche Abandons Tau Antibody Project, Returns Rights to UCB After $120M Investment
Roche, UCB, tau antibody, Alzheimer’s disease, bepranemab, $120M investment
UCB Expands Bimzelx Indications with Three New FDA Approvals for Chronic Inflammatory Diseases
Bimzelx, UCB, FDA approvals, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A, IL-17F inhibitor
UCB and Biogen Announce Positive Phase 3 Results for Dapirolizumab Pegol in Systemic Lupus Erythematosus, Plan Second Phase 3 Trial
UCB, Biogen, Dapirolizumab Pegol, Systemic Lupus Erythematosus, Phase 3 Trial, PHOENYCS GO, PHOENYCS FLY
UCB Divests Mature Neurology and Allergy Portfolio in China for $680M
UCB, China, neurology, allergy, divestment, CBC Group, Mubadala, pharmaceuticals, innovation, strategic partnerships
UCB Divests Chinese Production Plant and Older Medications for $680 Million
UCB, production plant, older medications, China, $680M, pharmaceutical industry, divestment
UCB’s Strategic Shift: Bristol Myers ADC Partner’s CEO Takes the Helm
UCB, management changes, CEO, Bristol Myers, ADC partner, strategic shift, pharmaceutical industry.